期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

艰难梭菌感染的治疗新药——非达霉素 被引量：7

Fidaxomicin——A New Drug for the Treatment of Clostridium difficile Infection
下载PDF
导出
摘要 非达霉素作为新型的大环内酯类抗生素,用于艰难梭菌感染的治疗。本文对非达霉素的化学结构、药理机制、抗菌活性、耐药机制、药动学性质、临床研究等方面作一综述。 Fidaxomicin is the antibiotic with a novel structure of macrolides for the treatment of Clostridium difficile infection.In this paper,the chemical structure,pharmacological mechanism,antibacterial activity,resistance mechanisms,pharmacokinetics and clinical trials of fidaxomicin were reviewed.
作者 肖宇博 于锋
机构地区 中国药科大学临床药学教研室
出处 《药学与临床研究》 2012年第5期419-424,共6页 Pharmaceutical and Clinical Research
关键词 非达霉素 艰难梭菌感染 作用机制 药动学 临床研究 Fidaxomicin Clostridium difficile infection Mechanism Pharmacokinetics Clinical trials
分类号 R978.15 [医药卫生—药品]
  • 相关文献

参考文献30

  • 1Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, heahhcare facility-asso- ciated Clostridium difficle infection and of heahhcare- associated infection due to methicillin-resistant Staphy- lococcus aureus in community hospitals [J]. Infect Con- trol Hosp Epidemiol, 2011, 32(4): 387-90.
  • 2McDonald LC, Killgore GE, Thompson A, et aL An epidemic, toxin gene-variant strain of Clostridium diffi- cile[J]. N Engl J Med, 2005, 353(23): 2433-441.
  • 3Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epi- demiology of America (SHEA) and the infectious dis- eases society of America (IDSA)[J]. Infect Control Hosp Epidemiol, 2010, 31(5): 431-55.
  • 4Check Orphan. Optimer pharmaceuticals receives or- phan drug designation for fidaxomicin for the treatment of pediatric Clostridium dicile infection [EB/OL]. [2011-01-12] http://www.checkorphan.org/index.php/grid/ news/treatment/optimer-pharmaceuticals-receives-orphan- drug -designation -for -fidaxomicin -for -the -treatment -of-pediatric-clostridium-difficile-infection.
  • 5FDA News FDA panel unanimously recommends approval of Optimer's fidaxomicin[EtL]. [2011--04-07] http://www. fdanews.com/newsletter/article? articleId --135696&issueId = 14618.
  • 6Coronelli C, White R J, Lancini GC, et al. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chem- ical, biological and biochemical characterization [J]. J Antibiot (Tokyo), 1975, 28(4): 253-9.
  • 7Parenti F, Pagani H, Beretta G, et al. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies [J]. J Antibiot (Tokyo), 1975, 28(4): 247-52.
  • 8Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis [J]. J Virol, 1980, 33(3): 945-53.
  • 9Wosten MM. Eubacterial sigma-factors[J]. FEMS Micro- [2 biol Rev, 1998, 22(3): 127-50.
  • 10Gualtieri M, Villain-Guillot P, Latouche J, et al. Mu- tation in the Bacillus subtilis RNA polymerase beta" subunit confers resistance to lipiarmycin[J]. Antimicrob Agents Chemother, 2006, 50(1): 401-2.

同被引文献80

  • 1丁维俊,周邦靖,翟慕东,白华.参苓白术散对小鼠脾虚模型肠道菌群的影响[J].北京中医药大学学报,2006,29(8):530-533. 被引量：117
  • 2楼淑瑾.抗生素相关性腹泻相关因素与对策[J].辽宁中医药大学学报,2006,8(6):120-121. 被引量：11
  • 3蒋兆年.肉蔻四神丸治疗抗生素相关性腹泻21例临床观察[J].首都医药,2007,14(11X):44-44. 被引量：7
  • 4Hall IC,O Toole E.Intestinal flora in newborn infants with a description of a new pathogenic anaerobe,Bacillus difficile.Am J Dis Child 1935; 48: 390-402.
  • 5Thomas C,Stevenson M,Riley TV.Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.J Antimicrob Chemother 2003; 51: 1339-1350.
  • 6Bartlett JG,Chang TW,Gurwith M,Gorbach SL,Onderdonk AB.Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.N Engl J Med 1978; 298: 531-534.
  • 7O'Connor D,Hynes P,Cormican M,Collins E,Corbett-Feeney G,Cassidy M.Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea.J Clin Microbiol 2001; 39: 2846-2849.
  • 8Mutters R,Nonnenmacher C,Susin C,Albrecht U,Kropatsch R,Schumacher S.Quantitative detection of Clostridium difficile in hospital environmental samples by real-time polymerase chain reaction.J Hosp Infect 2009; 71: 43-48.
  • 9Garg S,Mirza YR,Girotra M,Kumar V,Yoselevitz S,Segon A,Dutta SK.Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection.Dig Dis Sci 2013; 58: 3407-3412.
  • 10McDonald LC,Coignard B,Dubberke E,Song X,Horan T,Kutty PK.Recommendations for surveillance of Clostridium difficile-associated disease.Infect Control Hosp Epidemiol 2007; 28: 140-145.

引证文献7

二级引证文献11

药学与临床研究
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部